SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000891293-19-000033
Filing Date
2019-04-22
Accepted
2019-04-22 17:22:37
Documents
5
Effectiveness Date
2019-04-22

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14anoticeandaccess.htm DEFA14A 18313
2 defa14anoticeandacces_image1.gif GRAPHIC 37573
3 defa14anoticeandacces_image2.gif GRAPHIC 38423
4 defa14anoticeandacces_image3.gif GRAPHIC 18413
5 defa14anoticeandacces_image4.gif GRAPHIC 2515
  Complete submission text file 0000891293-19-000033.txt   153506
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-28386 | Film No.: 19760179
SIC: 2834 Pharmaceutical Preparations